Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Engel

Showing results (261-270 of 376) with videos related to

Pageof 38
Sort By:
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
International Journal of Cancer|May 14, 2019
Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillanceChristoph Engel, Christine Fischer, Silke Zachariae, et al.
NPJ Breast Cancer|May 13, 2021
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjectsNa Li, Magnus Zethoven, Simone McInerny, et al.
NEJM Evidence|June 12, 2024
A Patient-Level Meta-Analysis of Intensive Glucose Control in Critically Ill AdultsDerick Adigbli, Yang Li, Naomi Hammond, et al.
Cell Reports|November 2, 2022
Nuclear stabilization of p53 requires a functional nucleolar surveillance pathwayKatherine M Hannan, Priscilla Soo, Mei S Wong, et al.
Journal of the National Cancer Institute|June 27, 2023
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiationMark van Barele, Delal Akdeniz, Bernadette A M Heemskerk-Gerritsen, et al.
Gut|February 15, 2013
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European expertsHans F A Vasen, Ignacio Blanco, Katja Aktan-Collan, et al.
Journal of Medical Genetics|August 15, 2012
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer riskAmanda B Spurdle, Phillip J Whiley, Bryony Thompson, et al.
Gastroenterology|August 1, 2018
No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance PoliciesChristoph Engel, Hans F Vasen, Toni Seppälä, et al.
Cancer Medicine|March 10, 2018
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian CancerJan Hauke, Judit Horvath, Eva Groß, et al.
Pageof 38

Showing results (261-270 of 376) with videos related to

Sort By:
Pageof 38
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
International Journal of Cancer|May 14, 2019
Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillanceChristoph Engel, Christine Fischer, Silke Zachariae, et al.
NPJ Breast Cancer|May 13, 2021
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjectsNa Li, Magnus Zethoven, Simone McInerny, et al.
NEJM Evidence|June 12, 2024
A Patient-Level Meta-Analysis of Intensive Glucose Control in Critically Ill AdultsDerick Adigbli, Yang Li, Naomi Hammond, et al.
Cell Reports|November 2, 2022
Nuclear stabilization of p53 requires a functional nucleolar surveillance pathwayKatherine M Hannan, Priscilla Soo, Mei S Wong, et al.
Journal of the National Cancer Institute|June 27, 2023
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiationMark van Barele, Delal Akdeniz, Bernadette A M Heemskerk-Gerritsen, et al.
Gut|February 15, 2013
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European expertsHans F A Vasen, Ignacio Blanco, Katja Aktan-Collan, et al.
Journal of Medical Genetics|August 15, 2012
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer riskAmanda B Spurdle, Phillip J Whiley, Bryony Thompson, et al.
Gastroenterology|August 1, 2018
No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance PoliciesChristoph Engel, Hans F Vasen, Toni Seppälä, et al.
Cancer Medicine|March 10, 2018
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian CancerJan Hauke, Judit Horvath, Eva Groß, et al.
Pageof 38